PUBLISHER: The Business Research Company | PRODUCT CODE: 1939352
PUBLISHER: The Business Research Company | PRODUCT CODE: 1939352
Biopharmaceutical tubing refers to specialized tubing used in the production and handling of biopharmaceutical products. It is engineered to meet rigorous standards for sterility, biocompatibility, and precision to ensure the safe and effective handling of sensitive materials throughout both manufacturing and administration processes.
The main products in the biopharmaceutical tubing market include silicone tubing, polyvinyl chloride (PVC) tubing, polyolefin tubing, and thermoplastic elastomer tubing. Silicone biopharmaceutical tubing is known for its flexibility and high purity, made from silicone rubber and specifically designed for use in the biopharmaceutical industry. Manufacturing processes for these tubes include extrusion and vulcanization, with applications spanning pharmaceuticals, medical devices, research and development, and other areas.
Tariffs are influencing the biopharmaceutical tubing market by increasing the cost of specialty polymers, silicone compounds, extrusion-grade resins, and sterile packaging materials sourced through global supply networks, resulting in higher production and procurement expenses for manufacturers and end users. The impact is particularly evident across silicone, pvc, and thermoplastic elastomer tubing categories produced in Asia-Pacific and European industrial hubs that rely on imported raw materials and precision extrusion equipment. Pharmaceutical manufacturers, medical device producers, and research facilities are experiencing pricing pressures and extended sourcing cycles as tariff-related costs are passed along the supply chain. However, tariffs are also encouraging localized resin compounding, regional extrusion capabilities, and domestic component assembly, which may strengthen supply resilience and support long-term manufacturing competitiveness.
The biopharmaceutical tubing market research report is one of a series of new reports from The Business Research Company that provides biopharmaceutical tubing market statistics, including biopharmaceutical tubing industry global market size, regional shares, competitors with a biopharmaceutical tubing market share, detailed biopharmaceutical tubing market segments, market trends and opportunities, and any further data you may need to thrive in the biopharmaceutical tubing industry. This biopharmaceutical tubing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The biopharmaceutical tubing market size has grown rapidly in recent years. It will grow from $4.79 billion in 2025 to $5.32 billion in 2026 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to expansion of biopharmaceutical manufacturing capacity, increasing standardization of sterile processing components, early adoption of silicone and pvc tubing in drug production lines, growth in contract manufacturing and fill-finish activities, rising regulatory emphasis on material biocompatibility and purity.
The biopharmaceutical tubing market size is expected to see rapid growth in the next few years. It will grow to $8.12 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to growing pipeline of biologics and cell and gene therapy products, increasing shift toward single-use and disposable processing systems, higher demand for high-performance tpe and polyolefin tubing, expansion of automated production and closed system workflows, rising investment in advanced bioprocessing and aseptic transfer technologies. Major trends in the forecast period include increasing use of high-purity and biocompatible tubing in biopharmaceutical processing, rising adoption of single-use and sterile transfer tubing systems, growing demand for precision fluid handling in drug manufacturing and fill-finish operations, expansion of tubing applications across pharmaceutical, medical device, and r&d settings, focus on material durability, sterility assurance, and contamination control.
The growing number of personalized medicines is expected to drive the expansion of the biopharmaceutical tubing market in the coming years. Personalized medicine is a healthcare approach that customizes medical decisions, practices, interventions, and treatments based on the unique characteristics of each patient. The increasing focus on personalized medicine is largely driven by advances in genetic research, which allow treatment strategies to be tailored according to an individual's genetic makeup, lifestyle, and specific health conditions. Biopharmaceutical tubing plays a critical role in supporting personalized medicine by enabling accurate, sterile, and dependable fluid transfer, which is essential for administering customized therapies and treatments designed for individual patient needs. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration approved 26 new personalized therapies in 2023, compared to 18 approvals in 2022, representing one of the highest yearly increases in personalized medicine approvals. Therefore, the rising number of personalized medicines is contributing to the growth of the biopharmaceutical tubing market.
Key players in the biopharmaceutical tubing market are advancing their product offerings with next-generation solutions, such as bioabsorbable tubing, to enhance performance, sterility, and fluid handling for advanced biopharmaceutical applications. Bioabsorbable tubing is made from materials that gradually break down and are absorbed by the body, eliminating the need for removal after use. For example, in September 2023, Zeus Company Inc., a US-based provider of advanced polymer solutions, introduced the Absorv XSE-oriented tubing, a next-generation bioabsorbable product designed for bioresorbable vascular scaffolds (BRS). This innovation allows medical device manufacturers to explore BRS applications beyond treating coronary artery disease and potentially replace metallic stents in various procedures. The new tubing offers improved wall thickness and sizing uniformity, enhancing efficiency during laser cutting processes and resulting in more usable scaffolds.
In February 2024, EQT Private Equity, a Sweden-based investment management firm, acquired Zeus Company Inc. for $3.4 billion. This acquisition aims to support Zeus's growth by investing in additional production capacity, research and development, and operational excellence, particularly in medical tubing technology. Zeus Company Inc. is a US-based manufacturer known for precision polymer extrusions and custom tubing.
Major companies operating in the biopharmaceutical tubing market are Compagnie de Saint-Gobain S.A., Thermo Fisher Scientific Inc., Merck KGaA, GE HealthCare Technologies Inc., Parker Hannifin Corporation, DuPont de Nemours Inc., Freudenberg Group, Alfa Laval AB, REHAU Group, W. L. Gore & Associates Inc., Sartorius AG, Elkem ASA, Trelleborg AB, Bio-Rad Laboratories Inc., Tekni-Plex Inc., Pall Corporation, Zeus Company Inc., Watson-Marlow Ltd., Raumedic AG, Optinova AB, ESI Ultrapure
North America was the largest region in the biopharmaceutical tubing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical tubing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the biopharmaceutical tubing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The biopharmaceutical tubing market consists of sales of polytetrafluoroethylene (PTFE) tubing, ethylene-vinyl acetate (EVA) tubing, and rubber tubing. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Biopharmaceutical Tubing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses biopharmaceutical tubing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for biopharmaceutical tubing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biopharmaceutical tubing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.